Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cell Therapeutics Inc announces removal of the partial clinical hold on Tosedostat


Thursday, 2 Jan 2014 01:30am EST 

Cell Therapeutics Inc:Says it has received notification from the U.S. FDA that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue.Says Tosedostat is currently being studied in the United States and European Union in investigator-sponsored and cooperative group-sponsored Phase 2 trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). 

Company Quote

3.18
-0.15 -4.50%
23 Apr 2014